Press Releases and Events

PRESS RELEASES

Press Release | April 10, 2025

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | March 27, 2025

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly

READ MORE
Press Release | March 10, 2025

Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | February 27, 2025

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

READ MORE
Press Release | February 24, 2025

Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

READ MORE
Press Release | February 20, 2025

Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences

READ MORE
Press Release | February 10, 2025

Crinetics Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | January 10, 2025

Crinetics Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | January 10, 2025

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

READ MORE
Press Release | January 6, 2025

Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

READ MORE
5 / 24